Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Novartis ag source : Www.biospace.com save search
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Published: 2024-03-27 (Crawled : 11:00) - biospace.com/
CRBU | $3.91 -2.49% -2.3% 1.7M
|
Health Technology
|
| O: 1.58%
H: 0.58%
C: -0.39%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.24%
H: 0.42%
C: 0.4%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
TGTX | $13.82 -1.29% -1.27% 2.7M
|
Health Technology
|
| O: 0.71%
H: 0.39%
C: 0.13%
DTIL | $11.51 -10.57% -11.91% 220K
|
Health Technology
|
| O: 0.39%
H: 4.22%
C: 1.41%
precision business year update financial results
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Published: 2024-03-22 (Crawled : 08:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
MOR | News | $18.04 0.5% 0.44% 400K
|
Health Technology
|
| O: 0.94%
H: 0.11%
C: -0.11%
acquisition clearance novartis
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $19.07 0.79% 0.84% 460K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | News | $18.04 0.5% 0.44% 400K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Published: 2024-02-27 (Crawled : 15:30) - biospace.com/
TSVT | $5.06 4.12% 3.95% 900K
|
|
| O: 0.0%
H: 8.64%
C: 8.36%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -0.15%
H: 0.31%
C: 0.06%
BLBD | $34.22 -4.97% -5.32% 750K
|
Producer Manufacturing
|
| O: 1.02%
H: 1.29%
C: 1.17%
ALVR | $0.7569 2.99% 2.29% 550K
|
Health Technology
|
| O: -1.42%
H: 7.9%
C: 3.52%
ADAP | $0.987 -4.18% -3.23% 1.2M
|
Health Technology
|
| O: 3.05%
H: 5.92%
C: 1.18%
pdufa commercial
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
Published: 2023-12-08 (Crawled : 16:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $25.42 -1.05% 0.16% 40M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®
Published: 2023-12-07 (Crawled : 00:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -0.97%
H: 0.3%
C: -0.19%
avzivi fda biosimilar
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | $13.15 -0.61% 0.0% 1.5M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $19.07 0.79% 0.84% 460K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | News | $18.04 0.5% 0.44% 400K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Bioluminescence Ventures Emerges from Stealth with $477M AUM
Published: 2023-11-01 (Crawled : 12:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.52%
H: 0.04%
C: 0.04%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.16%
H: 0.7%
C: 0.57%
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
ALVO | $12.8 0.55% 0.31% 130K
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | $5.08 3.67% 5.77% 34K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
adl018 xolair candidate biosimilar study
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
AADI | $1.82 1.68% 1.65% 200K
|
Manufacturing
|
| O: 3.1%
H: 0.2%
C: -13.83%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
bioscience
Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: -0.13%
H: 0.06%
C: -1.02%
CERS | $1.64 -2.38% -3.07% 660K
|
Health Technology
|
| O: -1.3%
H: 5.92%
C: 0.66%
corporation
Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
Published: 2023-08-23 (Crawled : 12:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.56%
H: 0.1%
C: -0.32%
growth
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
Published: 2023-07-12 (Crawled : 12:20) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: 0.26%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
hope beacon education novartis trial
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
Published: 2023-07-10 (Crawled : 12:00) - biospace.com/
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 1.44%
H: 0.73%
C: 0.48%
leqvio fda disease treatment risk novartis heart
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA
Published: 2023-06-08 (Crawled : 13:20) - biospace.com/
DAWN 4 | $14.85 1.64% 1.75% 650K
|
Professional, Scientific, and T...
|
| O: -0.69%
H: 0.0%
C: -7.55%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 1.26%
H: 1.08%
C: 0.91%
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
|
| O: 1.57%
H: 3.07%
C: 1.53%
paxalisib therapeutics study
Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
Published: 2023-06-08 (Crawled : 13:20) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: -0.62%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 1.26%
H: 1.08%
C: 0.91%
disease novartis skin
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
Published: 2023-05-03 (Crawled : 00:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.33%
QURE | $4.67 -0.64% -0.64% 830K
|
Health Technology
|
| O: 0.4%
H: 3.8%
C: 2.37%
RARE | $44.11 4.25% 4.08% 910K
|
Health Technology
|
| O: 0.92%
H: 3.17%
C: 1.0%
RGNX | News | $17.03 -2.69% -2.88% 410K
|
Health Technology
|
| O: 0.05%
H: 5.85%
C: 3.74%
financial results
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
Published: 2023-04-25 (Crawled : 15:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 5.0%
H: 0.0%
C: -0.57%
ERAS | $1.84 -4.66% -4.61% 580K
|
|
| O: 0.0%
H: 2.59%
C: -3.7%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 4.24%
H: 0.68%
C: -0.77%
melanoma publication potential
Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter
Published: 2023-04-17 (Crawled : 11:00) - biospace.com/
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | News | $93.08 -0.13% 0.13% 1.1M
|
Health Technology
|
| O: 0.47%
H: 0.01%
C: -0.38%
LLY | News | $750.77 0.54% 0.22% 2.8M
|
Health Technology
|
| O: 0.07%
H: 0.24%
C: -0.71%
financial
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.